About the ABPI

The ABPI represents innovative resea​rch-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.

Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. We represent companies who supply more than 80 per cent of all branded medicines used by the NHS and who are researching and developing the majority of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome disease.

Globally our industry is researching and developing more than 7,000 new medicines.

The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry for statutory consultation requirements including the pricing scheme for medicines in the UK.​​​​​​​

Brexit Health Alliance

The NHS Confederation Brexit Health Alliance brings together the NHS, medical research, industry, patients and public health organisations and has set five priorities for the negotiators:

  1. Maximum levels of research and innovation collaboration
  2. Regulatory alignment for the benefit of patients and population health
  3. Preservation of reciprocal healthcare arrangements
  4. Robust coordination mechanisms on public health and wellbeing
  5. A strong funding commitment to the health and public health sectors

A document outlining the position of the Alliance can be found here.

Media enquiries


+44 (0) 20 7747 7147​​